公开(公告)号：US20060111370A1

公开(公告)日：2006-05-25

申请号：US11149027

申请日：2005-06-09

申请人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan Ye ,  Johannes Voigt ,  Corey Strickland ,  Elizabeth Smith ,  Andrew Stamford ,  William Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy Le ,  Kurt Saionz ,  Suresh Babu ,  Rachael Hunter ,  Michelle Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse

发明人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan Ye ,  Johannes Voigt ,  Corey Strickland ,  Elizabeth Smith ,  Andrew Stamford ,  William Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy Le ,  Kurt Saionz ,  Suresh Babu ,  Rachael Hunter ,  Michelle Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse

IPC分类号： A61K31/519 ,  A61K31/497 ,  A61K31/513 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4245 ,  C07D413/02 ,  C07D403/02

CPC分类号： C07D233/46 ,  C07D233/70 ,  C07D233/88 ,  C07D239/22 ,  C07D239/70 ,  C07D271/07 ,  C07D273/00 ,  C07D401/04 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D403/04 ,  C07D403/06 ,  C07D403/08 ,  C07D403/10 ,  C07D403/12 ,  C07D405/10 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/06

摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

公开(公告)号：US20080200445A1

公开(公告)日：2008-08-21

申请号：US11710582

申请日：2007-02-23

申请人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan Ye ,  Johannes Voigt ,  Corey Strickland ,  Elizabeth Smith ,  Andrew Stamford ,  William Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoxiang Liu ,  Tao Guo ,  Thuy Le ,  Kurt Saionz ,  Suresh Babu ,  Rachael Hunter ,  Michelle Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

发明人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan Ye ,  Johannes Voigt ,  Corey Strickland ,  Elizabeth Smith ,  Andrew Stamford ,  William Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Xiaoxiang Liu ,  Tao Guo ,  Thuy Le ,  Kurt Saionz ,  Suresh Babu ,  Rachael Hunter ,  Michelle Morris ,  Huizhong Gu ,  Gang Qian ,  Dawit Tadesse ,  Ying Huang ,  Guoqing Li ,  Jianping Pan ,  Jeffrey Misiaszek ,  Gaifa Lai ,  Jingqi Duo ,  Chuanxing Qu ,  Yuefei Shao

IPC分类号： A61K31/506 ,  A61K31/4178 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/541 ,  A61P31/00 ,  C07D233/02 ,  C07D271/00 ,  C07D413/14 ,  C07D409/14 ,  C07D409/04 ,  C07D403/06 ,  C07D401/14 ,  C07D401/12 ,  C07D401/10 ,  C07D401/06 ,  C07D239/04 ,  A61P9/00 ,  A61P25/00 ,  A61K31/5377 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498

CPC分类号： C07D233/88 ,  A61K31/4168 ,  A61K31/4178 ,  C07D239/22 ,  C07D401/06 ,  C07D401/10 ,  C07D403/06 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D417/10 ,  C07D417/14 ,  C07D495/10

摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula 1. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

公开(公告)号：US20070072852A1

公开(公告)日：2007-03-29

申请号：US11010772

申请日：2004-12-13

申请人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan Ye ,  Johannes Voigt ,  Corey Strickland ,  Elizabeth Smith ,  Andrew Stamford ,  William Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy Le ,  Kurt Saionz ,  Suresh Babu ,  Rachael Hunter

发明人： Zhaoning Zhu ,  Brian McKittrick ,  Zhong-Yue Sun ,  Yuanzan Ye ,  Johannes Voigt ,  Corey Strickland ,  Elizabeth Smith ,  Andrew Stamford ,  William Greenlee ,  Robert Mazzola ,  John Caldwell ,  Jared Cumming ,  Lingyan Wang ,  Yusheng Wu ,  Ulrich Iserloh ,  Tao Guo ,  Thuy Le ,  Kurt Saionz ,  Suresh Babu ,  Rachael Hunter

IPC分类号： A61K31/549 ,  A61K31/5395 ,  A61K31/513

CPC分类号： C07D233/88 ,  A61K31/4168 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/655 ,  A61K45/06 ,  C07D233/46 ,  C07D233/70 ,  C07D235/02 ,  C07D239/22 ,  C07D239/70 ,  C07D271/07 ,  C07D273/00 ,  C07D295/15 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/08 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D405/14 ,  C07D407/06 ,  C07D409/04 ,  C07D409/06 ,  C07D409/10 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D417/06 ,  Y02A50/411

摘要： Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein W is a bond, —C(═S)—, —S(O)—, —S(O)2—, —C(═O)—, —O—, —C(R6)(R7)—, —N(R5)— or —C(═N(R5))—; X is —O—, —N(R5)— or —C(R6)(R7)—; provided that when X is —O—, U is not —O—, —S(O)—, —S(O)2—, —C(═O)— or —C(═NR5)—; U is a bond, —S(O)—, —S(O)2—, —C(O)—, —O—, —P(O)(OR15)—, —C(═NR5)—, —(C(R6)(R7))b— or —N(R5)—; wherein b is 1 or 2; provided that when W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, U is not —S(O)—, —S(O)2—, —O—, or —N(R5)—; provided that when X is —N(R5)— and W is —S(O)—, —S(O)2—, —O—, or —N(R5)—, then U is not a bond; and R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic antagonist.

公开(公告)号：US20050119227A1

公开(公告)日：2005-06-02

申请号：US10910987

申请日：2004-08-04

申请人： Jared Cumming ,  Ulrich Iserloh ,  Andrew Stamford ,  Corey Strickland ,  Johannes Voigt ,  Yusheng Wu ,  Ying Huang ,  Yan Xia ,  Samuel Chackalamannil ,  Tao Guo ,  Douglas Hobbs ,  Thuy Le ,  Jeffrey Lowrie ,  Kurt Saionz ,  Suresh Babu

发明人： Jared Cumming ,  Ulrich Iserloh ,  Andrew Stamford ,  Corey Strickland ,  Johannes Voigt ,  Yusheng Wu ,  Ying Huang ,  Yan Xia ,  Samuel Chackalamannil ,  Tao Guo ,  Douglas Hobbs ,  Thuy Le ,  Jeffrey Lowrie ,  Kurt Saionz ,  Suresh Babu

IPC分类号： A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61K31/675 ,  C07D207/09 ,  C07D211/26 ,  C07D217/18 ,  C07D241/04 ,  C07D243/08 ,  C07D401/06 ,  C07D403/12 ,  C07D403/14 ,  C07D413/06 ,  C07F9/38

CPC分类号： C07D243/08 ,  C07D205/04 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/26 ,  C07D209/52 ,  C07D211/26 ,  C07D211/46 ,  C07D217/18 ,  C07D233/32 ,  C07D241/04 ,  C07D241/08 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D409/06 ,  C07D409/12 ,  C07D413/06

摘要： Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is R is —C(O)—N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

摘要翻译： 公开了下式的化合物或其药学上可接受的盐或溶剂化物，其中R 1是R是-C（O）-N（R 27） > 28 ）或其余变量如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的药物组合物和方法，其包含式I化合物与除式I以外的β-分泌酶抑制剂，HMG-CoA还原酶抑制剂，γ-分泌酶抑制剂， 甾族抗炎剂，N-甲基-D-天冬氨酸受体拮抗剂，胆碱酯酶抑制剂或抗淀粉样蛋白抗体。

公开(公告)号：US08892534B2

公开(公告)日：2014-11-18

申请号：US12168065

申请日：2008-07-03

申请人： Sabine Hamlescher ,  Hartmut K. Vogler ,  Suresh Babu

发明人： Sabine Hamlescher ,  Hartmut K. Vogler ,  Suresh Babu

IPC分类号： G06F17/30 ,  G06Q10/06 ,  G06Q10/10

CPC分类号： G06Q10/10 ,  G06Q10/06

摘要： A method and system for assessing data quality stored in an enterprise database is provided. In response to a request by a user, a pre-determined event, or other event, a profile is chosen from a list of profiles stored in a profile database based on the request, wherein the profile includes a set of rules for calculating data quality metrics and for triggering workflow processes. One or more data records are received from one or more enterprise databases. The data quality metrics of the one or more data records based on the set of rules for calculating data quality metrics is calculated. Based on the calculated data quality metrics and rules for triggering workflow, a determination is made regarding whether to trigger one or more workflow processes: and, if so, triggering the one or more workflow processes; and/or converting the calculated data quality metrics to a representation for display.

摘要翻译： 提供了一种用于评估存储在企业数据库中的数据质量的方法和系统。 响应于用户的请求，预定事件或其他事件，基于请求从配置文件数据库中存储的简档的列表中选择简档，其中，简档包括用于计算数据质量的一组规则 指标和触发工作流程。 从一个或多个企业数据库接收一个或多个数据记录。 计算基于用于计算数据质量度量的规则集合的一个或多个数据记录的数据质量度量。 基于用于触发工作流程的计算的数据质量度量和规则，确定是否触发一个或多个工作流过程;如果是，则触发一个或多个工作流过程; 和/或将所计算的数据质量度量转换为用于显示的表示。

公开(公告)号：US20050038691A1

公开(公告)日：2005-02-17

申请号：US10951841

申请日：2004-09-27

申请人： Suresh Babu

发明人： Suresh Babu

IPC分类号： G06Q10/00 ,  G06F17/60

CPC分类号： G06Q10/08 ,  G06Q10/06395 ,  G06Q10/20 ,  G06Q30/014

摘要： A computerized recall management tool permits an organization to recognize and proactively manage events that can indicate a need to initiate a product recall. Product performance data often is made available to an organization through automatic identification technologies. The recall management tool may include modules to recognize patterns of product defects from product performance data, to model an extent to which a product defect may proliferate throughout its distributed products, to alert operators when such patterns are detected, to manage regulatory reporting events and other notification milestones and to manage a recall itself.

摘要翻译： 计算机化的召回管理工具允许组织识别并主动管理可指示需要启动产品召回的事件。 产品性能数据通常通过自动识别技术提供给组织。 召回管理工具可以包括用于从产品性能数据识别产品缺陷模式的模块，以模拟产品缺陷在其分布式产品中可能扩散的程度，以便在检测到这种模式时警告操作者，管理监管报告事件和其他 通知里程碑和管理召回本身。

公开(公告)号：US20050027143A1

公开(公告)日：2005-02-03

申请号：US10487554

申请日：2002-08-23

申请人： Mohammad Salman ,  Purna Ray ,  Suresh Babu ,  Naresh Kumar

发明人： Mohammad Salman ,  Purna Ray ,  Suresh Babu ,  Naresh Kumar

IPC分类号： C07C29/147 ,  C07C33/14 ,  C07C45/29 ,  C07C47/225 ,  C07C67/343 ,  C07C403/14 ,  C07C45/45

CPC分类号： C07C403/14 ,  C07B2200/09 ,  C07C29/147 ,  C07C33/14 ,  C07C67/343 ,  C07C403/08 ,  C07C403/20 ,  C07C2601/16 ,  C07C69/608

摘要： The present invention relates to an industrially advantageous process for the preparation of beta-ionylidencacetaldehyde of structural Formula I, which is a key intermediate for the synthesis of vitamin A and related compounds such as tretinoin and isotretinoin.

摘要翻译： 本发明涉及一种工业上有利的制备结构式I的β-离子亚基乙醛的方法，其是合成维生素A和相关化合物如维A酸和异维A酸的关键中间体。

公开(公告)号：US08887123B2

公开(公告)日：2014-11-11

申请号：US12182199

申请日：2008-07-30

申请人： Tao Lin ,  Ming-Chien Shan ,  Suresh Babu ,  Chuan Li

发明人： Tao Lin ,  Ming-Chien Shan ,  Suresh Babu ,  Chuan Li

IPC分类号： G06F9/44 ,  G06Q10/06

CPC分类号： G06Q10/06

摘要： An operations management environment is integrated with an information technology infrastructure through an adaptor, the integration occurring while the information technology infrastructure performs one or more tasks. Data from the information technology infrastructure is received through the adapter. Relationships between the artifacts included in the information technology infrastructure are modeled based on the received data. A proposed modification to the information technology infrastructure is determined based on an external change. While the information technology infrastructure performs the one or more tasks, the response of the artifacts to the proposed modification is simulated using the modeled relationships. The response of the artifacts is monitored to determine if the proposed modification implements the external change. A modification is generated based on the proposed modification if the proposed modification implements the external change, and the information technology infrastructure is updated while the information technology infrastructure performs the one or more tasks.

摘要翻译： 操作管理环境通过适配器与信息技术基础设施集成，信息技术基础架构执行一个或多个任务时发生集成。 通过适配器接收信息技术基础设施的数据。 基于接收到的数据，对信息技术基础设施中包含的工件之间的关系进行建模。 基于外部变化确定对信息技术基础设施的修改。 当信息技术基础设施执行一个或多个任务时，使用建模的关系模拟人造物对所提出的修改的响应。 监视工件的响应以确定所提出的修改是否实现外部变化。 如果提出的修改实施外部变更，则基于所提出的修改生成修改，并且在信息技术基础设施执行一个或多个任务的同时更新信息技术基础设施。

公开(公告)号：US07912810B2

公开(公告)日：2011-03-22

申请号：US11399411

申请日：2006-04-07

申请人： Barbara Wittmann ,  Heinz Kagermann ,  Christiane Kuntz-Mayr ,  Suresh Babu

发明人： Barbara Wittmann ,  Heinz Kagermann ,  Christiane Kuntz-Mayr ,  Suresh Babu

IPC分类号： G06F7/00 ,  G06F17/00 ,  G06F17/30 ,  G06Q10/00

CPC分类号： G06Q10/08 ,  G06Q10/06 ,  G06Q10/0834 ,  G06Q20/102 ,  G06Q50/28

摘要： Systems, methods and computer readable media are provided for integrating carrier services. In one implementation, carrier services are integrated into an Enterprise Resource Planning (ERP) system utilizing an integration platform. The integration platform may include a first, second, and third components. The first, second, and third components may interact to utilize within the integration platform services offered by ERP vendors and carriers by discovering, setting up, testing, running and updating these services. As result, typical business scenarios, such as a order-to-cash process, may be enhanced.

摘要翻译： 提供系统，方法和计算机可读介质用于集成运营商服务。 在一个实现中，运营商服务被集成到使用集成平台的企业资源规划（ERP）系统中。 集成平台可以包括第一，第二和第三组件。 第一，第二和第三组件可以通过发现，建立，测试，运行和更新这些服务来在ERP供应商和运营商提供的集成平台服务内进行互动。 因此，可以增强典型的业务场景，例如订单到现金流程。

公开(公告)号：US20070027740A1

公开(公告)日：2007-02-01

申请号：US11475322

申请日：2006-06-26

申请人： Suresh Babu ,  Youneng Xiao ,  Jie Zhao ,  Christiane Kuntz-Mayr ,  Heinz Kagermann ,  Ramshankar Venkatasubramanian

发明人： Suresh Babu ,  Youneng Xiao ,  Jie Zhao ,  Christiane Kuntz-Mayr ,  Heinz Kagermann ,  Ramshankar Venkatasubramanian

IPC分类号： G06Q99/00 ,  G06F15/02 ,  G06F9/46

CPC分类号： G06Q10/00 ,  G06Q30/0633

摘要： Methods and apparatuses for interfacing an enterprise customer with a supplier are described herein. In one embodiment, in response to a request received from an enterprise customer via a first interface (e.g., a common or universal interface) of a Web service over the Internet for a service provided by a supplier, processing logic is configured to map the request from a first format compatible with the first interface to a second format compatible with a second interface coupling with a backend system of the supplier. Processing logic invokes a method of the backend system of the supplier via the second interface (e.g., supplier specific interface) to provide the requested service to the enterprise customer using information of the mapped request. The first interface is compatible with the requesting customer and the second interface is a specific interface to the backend system of the supplier. Functionality of mapping and the second interface are maintained by the supplier. Other methods and apparatuses are also described.

摘要翻译： 本文描述了用于将企业用户与供应商接口的方法和装置。 在一个实施例中，响应于通过因特网针对由供应商提供的服务的经由因特网的Web服务的第一接口（例如，公共或通用接口）从企业客户接收的请求，处理逻辑被配置为映射请求 从与第一接口兼容的第一格式到与与供应商的后端系统耦合的第二接口兼容的第二格式。 处理逻辑通过第二接口（例如，供应商专用接口）来调用供应商后端系统的方法，以使用映射请求的信息向企业客户提供所请求的服务。 第一个接口与请求的客户兼容，第二个接口是供应商后端系统的特定接口。 供应商维护映射功能和第二个界面。 还描述了其它方法和装置。